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COST-MINIMIZATION ANALYSIS OF BIOPSY-BASED RISK STRATIFICATION
TOOLS IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER PATIENTS
BASED ON RESULTS FROM PHYSICIAN CASE STUDIES
Zubek VB, Khan F, Karvir H
Aureon Biosciences, Inc., Yonkers, NY, USA
OBJECTIVES: Prostate Cancer (PCa) disease management is challenging due to the
uncertainty in risk at diagnosis. Patients classified by the American Urological
Association (AUA) as intermediate (IR) or high risk (HR) may be guided to therapies
that are expensive and unnecessarily impact quality of life. Prostate Px is a biop-
sy-based assay that provides improved prognostic information and aims to facili-
tate more appropriate disease management. We performed a cost-minimization
analysis of PCa management according to standard care and of management post
Px, based on case studies reviewed by urologists. This study is an extension of
previous IR work which employed theoretical treatment distributions rather than
leveraging actual physician recommendations based on case studies. METHODS:
23 urologists nationwide reviewed case studies of PCa patients and recommended
treatments with and without the Px results. 233 AUA IR (83%) and HR (17%) cases
were analyzed. A decision analysis model, accounting for five primary treatments
(radical prostatectomy, radiation therapy, primary hormonal therapy, brachyther-
apy and active surveillance) plus secondary treatments, was used to compare stan-
dard care with management post Px reclassification. Both primary treatment
distributions and probabilities of Px reclassification were based on the physician
case studies. The disease progression models were informed with costs and prob-
abilities from the literature. The analysis is from Medicare’s perspective with a 10
year time horizon. RESULTS: The expected cost per patient of standard manage-
ment was $35,886 and $33,997 for Px (including the $3,200 list price), resulting in
an expected cost savings of $1,889. One-way sensitivity analysis of 40 variables
confirmed that modeled management post Px saves costs for all but three values
of progression probabilities post radical prostatectomy. CONCLUSIONS: Personal-
ized risk assessment tools such as Px improve PCa risk stratification of clinically
challenging intermediate and high risk patients, impacting disease management
and potentially saving costs over current standards.
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PATIENT TIME AND INDIRECT COSTS ASSOCIATED WITH
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Kamble S1, Weinfurt KP2, Perry BM3, Schulman KA1, Reed SD1
1Duke Clinical Research Institute, Durham, NC, USA, 2Duke University Medical Center, Durham,
NC, USA, 3Medtronic Diabetes, Northridge, CA, USA
OBJECTIVES: In a recent randomized trial, sensor-augmented pump therapy
(SAPT) demonstrated improved glucose control in Type 1 diabetes patients com-
pared to multiple daily injections of insulin (MDI). It is important to evaluate pa-
tient time demands to achieve clinical benefits of SAPT. Using data from this trial,
we compared reported estimates of weekly time, changes in time estimates across
the 52-week study period, and indirect costs associated with diabetes-related care
between treatments.METHODS:During the 52-week trial, patients (age 7-70 years,
n483) provided weekly time estimates for diabetes-related care. Given a distinct
difference in the distributions of patient time between treatments during the pump
initiation period, we used nonparametric bootstrapping to estimate the average
weekly time difference and its associated uncertainty for Weeks 1-7. For Weeks
8-52, we applied a linear mixed model to evaluate the incremental time spent by
patients on SAPT (versusMDI) and changes inweekly time for both treatments.We
compared indirect costs using nonparametric bootstrapping. RESULTS: At base-
line, MDI patients spent an average of 4.0 hours on diabetes-related care. During
the pump initiation period, patients on SAPT versus MDI spent 1.9 hours more per
week (95%CI: 1.2, 2.6). Following this period, SAPTpatients spent 4.4 hours perweek
andMDI patients spent 3.4 hours per week on diabetes-related care (difference:1.0,
95%CI: 0.4, 1.7). On average, time spent by patients in both treatments decreased by
1.2 minutes per week (95%CI:1.7,-0.7), acrossWeeks 8-52. Total indirect costs per
patient averaged $4,600 with SAPT and $3,523 with MDI (difference: $1,077, 95%CI:
$491, $1,638). CONCLUSIONS: Patients on SAPT versus MDI spent approximately
two hours more per week on diabetes care during pump initiation and one hour
more per week thereafter, resulting in higher indirect costs. This additional effort
was associated with significant improvement in glycated hemoglobin levels with
SAPT.
Medical Device/Diagnostics – Patient-Reported Outcomes & Preference-Based
Studies
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IMPACT OF ACCESS TO A USUAL SOURCE OF CARE ON COMPLIANCE TO
BREAST AND CERVICAL CANCER SCREENING
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OBJECTIVES: Trends in compliance to cancer screening among women have been
decreasing during the last ten years. In addition, Healthy People 2010 has noticed a
decline in the prevalence of a usual source of care in the American women. The
objective of this study was to assess the impact of access to a usual source of care
on compliance to mammography and PAP smear screening. METHODS: The 2007
Medical Expenditure Panel Survey (MEPS) data was used. Screening guidelines
gives by the American Cancer Society were used as a measure of compliance.
Multivariate logistic regressions were performed to determine associations be-
tween access to a usual source of care and compliance to mammography and PAP
smear while controlling for appropriate demographic characteristics. Sample was
weighted and analysiswas performedusing SPSS (PASW) 17.0.RESULTS: 80%of the
US non-institutionalized women population had a usual source of care in 2007.
59.1% women aged 41-70 years showed compliance to mammography guidelines.
Women who had a usual source of care, had a higher likelihood of mammography
compliance (OR2.540; CI: 2.535 – 2.545). 80.2%women aged 22-70 years were com-
pliant to PAP smear. Women who had a usual source of care showed a higher
likelihood of PAP smear compliance (OR2.041; CI: 2.038 – 2.044). CONCLUSIONS:
The results indicate that prevalence of mammography and PAP smear is de-
creasing and is still below the required Healthy People 2010 objectives of 70% and
90% respectively. Access to a usual source of care is essential for increased com-
pliance with mammography and PAP smear screening. This study indicates that
amendments made at the entry level of the healthcare systemmight help achieve
better health outcomes in the future. Public policies should be developed to en-
courage the concept of a usual source of care so as to achieve increased use of
preventive care.
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OBJECTIVES: Diabetic gastroparesis (DG) poses a significant economic and clinical
burden due to poorly understood physiological mechanisms and unresponsive-
ness to many medical treatments. Gastric electric stimulation (GES) is a treatment
modality that aims to reduce symptoms of nausea and vomiting associated with
gastroparesis in medically refractory patients. The aims of this analysis were: 1) to
compare HRQOL in DG patients to patients with common chronic diseases; and 2)
to determine the impact of GES on health state utilities. METHODS: HRQOL data
was collected during a prospective randomized controlled trial where a gastric
electric stimulator was implanted in patients with refractory DG (n55). Following
implant, the device was turned ON for 1.5 months after which patients were ran-
domized to groups having consecutive cross over periods with the device turned
ON or OFF. Per protocol, after cross over the device was turned ON for the remain-
ing period of the trial. SF-36 results at baseline and at 12 months were used for
analysis. Domain scores were compared to published population norms and aver-
age scores for common chronic conditions. Scores were also used to compute
health state utilities using Nichols and colleagues’ mapping algorithm. RESULTS:
Mean SF-36 domain scores for enrolled patients were lower than scores published
for population norms, and for persons with diabetes and other chronic conditions.
Mean health state utility values for patients prior to device implantation was 0.54
(0.50-0.59); implanting GES resulted in an improvement in health state utilities to
0.65 (0.60-0.71), which was statistically significant (p0.001). CONCLUSIONS: Pa-
tients with refractory DG had significantly worse health state utilities compared to
patients with serious medical conditions. Using GES for a period of approximately
9 months resulted in significant improvements in HRQOL for patients whose DG
was refractory to currently available medications.
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OBJECTIVES: To elicit preferences for genetic testing and estimate the relative
importance and value of features of genetic testing for colon cancer. METHODS:
United States residents aged 50 years and older completed a web-enabled, choice-
format conjoint survey. The survey presented subjects with 9 test-choice ques-
tions. Each question required evaluating a pair of hypothetical blood-test profiles
defined by chance of developing colon cancer, chance of receiving a false-negative
result, person who receives the genetic-test results, and personal cost versus a
no-test option. Test-choice questions were based on a predetermined experimen-
tal design with known statistical properties. The survey also elicited preferences
for colorectal-cancer risk reduction conditional on information that subjects had
Lynch syndrome gene associated with a high risk for colon cancer. Subjects were
asked to choose between a given number of lifetime colonoscopies or a colectomy
at specified costs to reduce the risk of dying from colorectal cancer. Random-
parameters logit was used to estimate model parameters, predicted testing prob-
abilities for specific tests, and the money-equivalent value of genetic information.
RESULTS: A total of 451 subjects completed the survey. Given the range of levels of
each attribute in the study, themost important attributewas cost, followed bywho
else sees the test results, the genetic-testing preference, and chance of a false-
negative test result. For the “best” test compared with no test where the best test
has 0% chance of a false-negative test result, results are disclosed to a physician,
and cost is $500; the predicted probability of choosing the test is 97% (CI: 95%-99%).
Setting the test attributes to themean effect, the overallmonetary value for genetic
testing was $622. CONCLUSIONS: Cost and the potential for insurance discrimina-
tion based on genetics are the most important considerations in testing decisions
and are more important than test accuracy and reduction of cancer risk.
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